Ms. Fengyu Wu has over 15 years of experience in drug development and medical affairs. She joined EdiGene in 2022 as Sr. Medical Director, Head of Clinical Affairs.

Before EdiGene, Mrs. Wu had 10 years of clinical development experience in solid tumors and hematological diseases for phase I to phase III studies from global top CROs, big pharma and biotech such as Adamadle, Hengrui Pharmaceuticals, JW Therapeutics, COVANCE and APEX. She also had 6 years of experience in medical affairs at Novartis, Merck Serono, and MSD.

She received her Master’s Degree in Obstetrics and Gynecology from Tianjin Medical University.